Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 67,993	$ 25,218
Short-term investments	599,032	708,737
Accounts receivable	30,220	22,492
Inventory	15,379	15,801
Other current assets	20,831	23,333
Total current assets	733,455	795,581
Long-term investments	37,363	64,828
Property, plant and equipment, net	60,980	60,510
Operating lease right-of-use assets	114,296	117,025
Goodwill	76,501	76,501
Other assets	1,521	2,744
Total assets	1,024,116	1,117,189
Current liabilities:
Accounts payable	12,617	9,747
Accrued compensation	22,653	15,735
Accrued clinical trial expenses	33,403	26,809
Other accrued expenses	17,011	15,468
Operating lease liabilities, current portion	19,597	17,441
Total current liabilities	105,281	85,200
Operating lease liabilities, less current portion	122,638	125,736
Development derivative liability	0	27,726
Liabilities related to the sales of future royalties, net	185,604	195,427
Other long-term liabilities	2,704	3,592
Total liabilities	416,227	437,681
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2022 or December 31, 2021, respectively	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 186,274 shares and 185,468 shares outstanding at March 31, 2022 or December 31, 2021, respectively	19	19
Capital in excess of par value	3,537,790	3,516,641
Accumulated other comprehensive loss	(6,532)	(4,157)
Accumulated deficit	(2,923,388)	(2,832,995)
Total stockholders’ equity	607,889	679,508
Total liabilities and stockholders’ equity	$ 1,024,116	$ 1,117,189